Key result
Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
Why the study?
Does fondaparinux provide effective anticoagulation in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids?
Does fondaparinux provide effective anticoagulation in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids?
Fondaparinux may serve as an effective alternative anticoagulant for pregnant women at high risk of VTE who are intolerant to LMWH and heparinoids.
May support fondaparinux in select high-risk pregnant VTE patients intolerant to LMWH; leaves open need for prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Zotz et al. (2007) studied Venous thromboembolism in pregnancy. Fondaparinux was evaluated. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: